Ishii H, Brunet JA, Welsh RP, Uhthoff HK (1997). ""Bursal reactions" in rotator cuff tearing, the impingement syndrome, and calcifying tendinitis". J Shoulder Elbow Surg. 6 (2): 131–6. doi:10.1016/S1058-2746(97)90033-1. PMID 9144600. McAfee JH, Smith DL (1988). "Olecranon and prepatellar bursitis. Diagnosis and treatment". West. J. Med. 149 (5): 607–10. PMC 1026560. PMID 3074561. Perry J (1983). "Anatomy and biomechanics of the shoulder in throwing, swimming, gymnastics, and tennis". Clin Sports Med. 2 (2): 247–70. doi:10.1016/S0278-5919(20)31406-X. PMID 9697636. Reilly JP, Nicholas JA (1987). "The chronically inflamed bursa". Clin Sports Med. 6 (2): 345–70. doi:10.1016/S0278-5919(20)31035-8. PMID 3319205.Trojian T, Stevenson JH, Agrawal N (2005). "What can we expect from nonoperative treatment options for shoulder pain?". J Fam Pract. 54 (3): 216–23. PMID 15755374. Shamus, Jennifer; Shamus, Eric (2001). Sports injury: prevention & rehabilitation. New York: McGraw-Hill Medical Pub. Div. ISBN 978-0-07-135475-2. Starr M, Harbhajan K (June 2001). "Recognition and Management of Common Forms of Tendinitis and Bursitis" (PDF). The Canadian Journal of Continuing Medical Education: 155–63. ISSN 0843-994X. Trojian T, Stevenson JH, Agrawal N (2005). "What can we expect from nonoperative treatment options for shoulder pain?". J Fam Pract. 54 (3): 216–23. PMID 15755374.
van Holsbeeck M, Strouse PJ (1993). "Sonography of the shoulder: evaluation of the subacromial-subdeltoid bursa". AJR Am J Roentgenol. 160 (3): 561–4. doi:10.2214/ajr.160.3.8430553. PMID 8430553. Yanagisawa K, Hamada K, Gotoh M,  et al. (2001). "Vascular endothelial growth factor (VEGF) expression in the subacromial bursa is increased in patients with impingement syndrome". J. Orthop. Res. 19 (3): 448–55. doi:10.1016/S0736-0266(00)90021-4. PMID 11398859. S2CID 20098903.
Dosing guidelines were published at that time.Concerns over the high incidence of reported side effects with ketorolac trometamol led to its withdrawal (apart from the ophthalmic formulation) in several countries, while in others its permitted dosage and maximum duration of treatment have been reduced. From 1990 to 1993, 97 reactions with a fatal outcome were reported worldwide.The eye-drop formulation was approved by the FDA in 1992.An intranasal formulation (Sprix) was approved by the FDA in 2010 for short-term management of moderate to moderately severe pain requiring analgesia at the opioid level. Ketorolac has also been used in collegiate and professional sports, and is reported to be routinely used in the National Football League and National Hockey League. Competitive athletes, particularly in contact sports, are often expected by their coaches and/or teammates to play through injuries, generally with the help of painkillers. However, more recent research has indicated that encouraging players to play in an injured state tends to result in more severe injuries. A lawsuit alleging widespread league-sanctioned abuse of painkillers was filed by former players against the National Football League in 2017. References
Further reading
External links
"Ketorolac". Drug Information Portal. U.S. National Library of Medicine.